37 search results for: symptoms

expert video

What Could Remission Mean in AD?

1 min

Dermatology

Dr. Simpson explores the concept of remission in AD, focusing on minimal disease activity and long-term remission, discussing how disease modification in AD can impact the course of the disease and its associated comorbidities.

interactivity

Chronic Spontaneous Urticaria (CSU) Interactive Patient Case

10 min

Dermatology

Learn more about the guideline-based diagnosis of chronic spontaneous urticaria with this interactive patient case.

expert video

The Clinical Presentation of CSU is Heterogeneous

3 min

Dermatology

Dr Hawkes provides an overview of the distinctive characteristics of wheals and angioedema in clinical manifestation

expert video

New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children

12 min

Dermatology

Dr. Stephan Weidinger describes the roles of IL-4 and IL-13 in skin barrier dysfunction, and the potential of early control of type 2 inflammation to modify disease course. This video was recorded at the EADV 2023 annual meeting during the ‘New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management’ presentation.

expert video

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

3 min

Dermatology

Dr. Marlies de Graaf highlights the potential long-term consequences of AD in children.

expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

3 min

Dermatology

Dr. Stephan Weidinger describes the relationship between skin barrier dysfunction and increased risk of allergen sensitization in AD.

expert video

Comorbidities and Disease Burden in CSU

10 min

Dermatology

In their interview Drs. Maurer and Ensina shed light on the significant burden of comorbidities in CSU.

interactivity

Prurigo Nodularis: The Patient Journey

5 min

Dermatology

An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.

expert video

New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management

29 min

Dermatology

Review the evolving therapeutic landscape for children with AD, considering clinically relevant data supporting the use of advanced systemic therapies.

Podcast

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

20 min

Dermatology

This podcast episode looks at the epidemiology, clinical presentation and classification of atopic dermatitis of the hand and feet and the impact it has on patients' quality of life.

Podcast

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

20 min

Dermatology

Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique features of prurigo nodularis (PN) as well as the characteristics that are shared with atopic dermatitis, and aim to raise awareness of PN among both physicians and patients.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region